{"schema_version":"secwatch.filing_event.v1","accession":"0000896264-25-000054","form_type":"8-K","ticker":"USNA","cik":"0000896264","company_name":"USANA HEALTH SCIENCES INC","filed_at":"2025-02-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.729545+00:00","generated_at":"2026-05-26T05:19:27.119975+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"USANA Q4 net sales -3% to $214M; net earnings -73% to $4.5M; FY2025 guidance includes Hiya","bullets":["Q4 net sales $214M (-3% YoY); net earnings $4.5M (-73%); diluted EPS $0.23 (-74%).","FY2024 net sales $855M (-7% YoY); net earnings $42M (-34%); diluted EPS $2.19.","Active customers 454K (-6% YoY); Americas & Europe net sales +1% YoY, Asia Pacific -6%.","Closed acquisition of 78.8% of Hiya on Dec 23, 2024; contributed ~$2M in Q4 sales.","FY2025 outlook: net sales $920M–$1.0B; diluted EPS $1.50–$2.20; adjusted diluted EPS $2.35–$3.00."],"urls":{"canonical":"https://secwatch.observer/filing/0000896264-25-000054","json":"https://secwatch.observer/filing/0000896264-25-000054.json","markdown":"https://secwatch.observer/filing/0000896264-25-000054.md","text":"https://secwatch.observer/filing/0000896264-25-000054.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/896264/000089626425000054/0000896264-25-000054-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/896264/000089626425000054/usna-20250225.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T05:19:27.119975+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}